Satsuma Pharmaceuticals (NASDAQ: STSA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-09 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.490 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Satsuma Pharmaceuticals (NASDAQ: STSA) through any online brokerage.
Other companies in Satsuma Pharmaceuticals’s space includes: Marinus Pharma (NASDAQ:MRNS), Anebulo Pharmaceuticals (NASDAQ:ANEB), Endo International (NASDAQ:ENDP), Trevi Therapeutics (NASDAQ:TRVI) and Adamis Pharmaceuticals (NASDAQ:ADMP).
The latest price target for Satsuma Pharmaceuticals (NASDAQ: STSA) was reported by Mizuho on Friday, May 13, 2022. The analyst firm set a price target for 13.00 expecting STSA to rise to within 12 months (a possible 200.93% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Satsuma Pharmaceuticals (NASDAQ: STSA) is $4.32 last updated July 1, 2022, 8:00 PM UTC.
A quarterly cash dividend of $0.20 per share of Class A Common Stock. The quarterly cash dividend was payable on April 15, 2014 to stockholders of record on March 28, 2014.
Satsuma Pharmaceuticals’s Q2 earnings are confirmed for Tuesday, August 9, 2022.
There is no upcoming split for Satsuma Pharmaceuticals.
Satsuma Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.